#87 Psoriasis treated successfully with ustekinumab in a cocaine-addicted patient.
Rallis E, Korfitis C, Katoulis A, Katsarou A. J Dermatol Case Rep. 2013;7:82-3.
#86 Amyopathic dermatomyositis-associated bilateral elbow ulcers successfully treated with autologous platelet-rich plasma.
Rallis E, Falidas E, Villias C. Int J Dermatol. 2014;53:e50-2.
#85 Isotretinoin for the treatment of granulomatous rosacea: case report and review of the literature.
Rallis E, Korfitis C. J Cutan Med Surg. 2012;16:438-41.
#84 Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in an HBsAg negative anti-HBs positive patient.
Koskinas J, Tampaki M, Doumba PP, Rallis E. Br J Dermatol. 2013;168:679-80.
#83 The role of terbinafine in induction and/or exacerbation of psoriasis.
Verros CD, Rallis E. Int J Dermatol. 2013;52:1155-6.
#82 Alopecia areata during ustekinumab administration: Co-existence or an adverse reaction?
Verros C, Rallis E, Crowe M. Dermatol Online J. 2012;18:14.
#81 Tuberous sclerosis in a patient with situs inversus totalis and polysplenia.
Rallis E, Giannopoulos C, Korfitis C, Kyriakos N, Liatsos C. Indian J Dermatol Venereol Leprol. 2012;78:520.
#80 Erlotinib-induced scalp perifolliculitis.
Rallis E, Petronic-Rosic V, Korfitis C. Skinmed. 2012;10:70-1.
#79 Peripheral nerve sheath tumour mimicking thrombophlebitis.
Doukoumopoulos I, Falidas E, Rallis E, Villias C. ANZ J Surg. 2012;82:88.
#78 Mycobacterium marinum cutaneous infection with sporotrichoid distribution treated with azithromycin monotherapy.
Rallis E, Falidas E, Stavropoulos P. Skinmed. 2012;10:54-5.
#77 Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.
Konsta M, Rallis E, Karameris A, Stratigos A, Sfikakis PP, Iliopoulos A. J Eur Acad Dermatol Venereol. 2012;26:257-8.
#76 Malignant fibrous histiocytoma masquerading as gluteal abscess.
Falidas E, Rallis E, Ntatsi A, Mathioulakis S, Villias C J Cutan Med Surg. 2011;15:354-5.
